English Español
Back to Clinical Trials

Brief Title: Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

An Open-label, Randomized, Controlled Phase 3 Study of Enfortumab Vedotin in Combination With Pembrolizumab Versus Chemotherapy Alone in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

INTRODUCTION

  • Org Study ID: SGN22E-003
  • Secondary ID: 2019-004542-15, MK-3475-A39, KEYNOTE KN-A39, jRCT2031200284
  • NTC ID: NCT04223856
  • Sponsor: Astellas Pharma Global Development, Inc.

DESCRIPTION

This clinical trial uses a drug called enfortumab vedotin. The Food and Drug Administration (FDA) has approved enfortumab vedotin for sale in the US. It’s approved for adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter, or urethra) that has been treated before and that has spread or cannot be removed by surgery. 

We are studying enfortumab vedotin to find out if it works for your type of cancer when given with other drugs. We want to see if this drug combination works better than the available approved treatments. We also want to learn more about the side effects. A side effect is anything the drug does to your body besides treating your disease. We don’t yet know if enfortumab vedotin works better or worse than other treatments when combined with other drugs. Learning how this drug combination works and about the side effects will help us understand if it works better or worse than other treatments.

The drug we are using in this study in combination with enfortumab vedotin is pembrolizumab (brand name KEYTRUDA®). Pembrolizumab is approved by the FDA to treat several types of cancer, including cancer of the urinary system, in some people. This clinical trial also uses chemotherapy drugs such as cisplatin, carboplatin, and gemcitabine. These chemotherapy drugs are approved by the FDA for treating various cancers.

 

BRIEF SUMMARY

This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together to treat patients with urothelial cancer. The study will compare these drugs to other drugs that are usually used to treat this cancer (standard of care). The patients in this study will have cancer that has spread from their urinary system to other parts of their body.

DETAILED DESCRIPTION

Japan PMDA has approved enfortumab vedotin (Padcev) for the treatment of advanced urothelial cancer. The study will continue as a post marketing study in Japan.

This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care gemcitabine + platinum-containing chemotherapy, in subjects with previously untreated locally advanced or metastatic urothelial cancer.

Enfortumab vedotin may be administered for an unlimited number of cycles until a protocol defined reason for study discontinuation occurs. Pembrolizumab may be administered for a maximum of 35 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first. Cisplatin or carboplatin plus gemcitabine may be administered for a maximum of 6 cycles or a protocol-defined reason for study discontinuation occurs, whichever is first.

  • Overall Status
    Recruiting
  • Start Date
    March 30, 2020
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Duration of progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by blinded independent central review (BICR) (Arms A and B only)

Primary Outcome 1 - Timeframe: Up to approximately 5 years

Primary Outcome 2 - Measure: Duration of Overall survival (OS) (Arms A and B only)

Primary Outcome 2 - Timeframe: Up to approximately 5 years

CONDITION

  • Urothelial Cancer

ELIGIBILITY

Inclusion Criteria:
Histologically documented, unresectable locally advanced or metastatic urothelial carcinoma
Measurable disease by investigator assessment according to RECIST v1.1
Participants with prior definitive radiation therapy must have measurable disease per RECIST v1.1 that is outside the radiation field or has demonstrated unequivocal progression since completion of radiation therapy
Participants must not have received prior systemic therapy for locally advanced or metastatic urothelial carcinoma with the following exceptions:
Participants that received neoadjuvant chemotherapy with recurrence >12 months from completion of therapy are permitted

- Participants that received adjuvant chemotherapy following cystectomy with recurrence >12 months from completion of therapy are permitted

- Must be considered eligible to receive cisplatin- or carboplatin-containing chemotherapy, in the investigator's judgment

- Archival tumor tissue comprising muscle-invasive urothelial carcinoma or a biopsy of metastatic urothelial carcinoma must be provided for PD-L1 testing prior to randomization

- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2

- Adequate hematologic and organ function
Exclusion Criteria
Previously received enfortumab vedotin or other monomethyl auristatin E (MMAE)-based antibody-drug conjugate (ADCs)

- Received prior treatment with a programmed cell death ligand-1 (PD-(L)-1) inhibitor for any malignancy, including earlier stage urothelial cancer (UC), defined as a PD-1 inhibitor or PD-L1 inhibitor

- Received prior treatment with an agent directed to another stimulatory or co inhibitory T-cell receptor

- Received anti-cancer treatment with chemotherapy, biologics, or investigational agents not otherwise prohibited by exclusion criterion 1-3 that is not completed 4 weeks prior to first dose of study treatment

- Uncontrolled diabetes

- Estimated life expectancy of less than 12 weeks

- Active central nervous system (CNS) metastases

- Ongoing clinically significant toxicity associated with prior treatment that has not resolved to ≤ Grade 1 or returned to baseline

- Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted.

- Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.

- History of another invasive malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy

- Documented history of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association (NYHA) Class IV within 6 months prior to randomization

- Receipt of radiotherapy within 2 weeks prior to randomization

- Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization

- Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin

- Active keratitis or corneal ulcerations

- History of autoimmune disease that has required systemic treatment in the past 2 years

- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan

- Prior allogeneic stem cell or solid organ transplant

- Received a live attenuated vaccine within 30 days prior to randomization

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Sujata Narayanan, MD, MS

Role: Study Director

Affiliation: Seagen Inc.

Overall Contact

Name: Sujata Narayanan, MD, MS

Phone: 866-333-7436

Email: clinicaltrials@seagen.com

LOCATION

Facility Status Contact
Facility: City of Hope National Medical Center
Duarte, California 91010
United States
Status: Recruiting Contact: N/A
Facility: University of California Los Angeles Medical Center
Los Angeles, California 90095
United States
Status: Recruiting Contact: N/A
Facility: University of California Irvine - Newport
Orange, California 92868
United States
Status: Recruiting Contact: N/A
Facility: Rocky Mountain Cancer Centers - Aurora
Aurora, Colorado 80012
United States
Status: Recruiting Contact: N/A
Facility: University of Colorado Hospital / University of Colorado
Aurora, Colorado 80045
United States
Status: Recruiting Contact: N/A
Facility: Cancer Centers of Colorado - Denver
Denver, Colorado 80218
United States
Status: Recruiting Contact: N/A
Facility: Yale Cancer Center
New Haven, Connecticut 06520
United States
Status: Recruiting Contact: N/A
Facility: Eastern CT Hematology and Oncology Associates
Norwich, Connecticut 06360
United States
Status: Recruiting Contact: N/A
Facility: Lombardi Cancer Center / Georgetown University Medical Center
Washington, District of Columbia 20007
United States
Status: Recruiting Contact: N/A
Facility: H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida 33612
United States
Status: Recruiting Contact: N/A
Facility: Winship Cancer Institute / Emory University School of Medicine
Atlanta, Georgia 30322
United States
Status: Recruiting Contact: N/A
Facility: Maine Health Cancer Care
Biddeford, Maine 04046
United States
Status: Recruiting Contact: N/A
Facility: Johns Hopkins Medical Center
Baltimore, Maryland 21231
United States
Status: Recruiting Contact: N/A
Facility: Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada 89169
United States
Status: Recruiting Contact: N/A
Facility: New Mexico Cancer Center
Albuquerque, New Mexico 87109
United States
Status: Recruiting Contact: N/A
Facility: New York University (NYU) Cancer Institute
New York, New York 10016
United States
Status: Recruiting Contact: N/A
Facility: Mount Sinai Medical Center
New York, New York 10029
United States
Status: Recruiting Contact: N/A
Facility: Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Status: Recruiting Contact: N/A
Facility: Vidant Medical Center
Greenville, North Carolina 27834
United States
Status: Recruiting Contact: N/A
Facility: The Cleveland Clinic
Cleveland, Ohio 44195
United States
Status: Recruiting Contact: N/A
Facility: University of Texas Southwestern Medical Center
Dallas, Texas 75390
United States
Status: Recruiting Contact: N/A
Facility: UT Health East Texas Hope Cancer Center
Tyler, Texas 75701
United States
Status: Recruiting Contact: N/A
Facility: Huntsman Cancer Institute
Salt Lake City, Utah 84112
United States
Status: Recruiting Contact: N/A
Facility: University of Virginia
Charlottesville, Virginia 22908
United States
Status: Recruiting Contact: N/A
Facility: Seattle Cancer Care Alliance / University of Washington
Seattle, Washington 98109
United States
Status: Recruiting Contact: N/A
Facility: Site AR54011
Caba, Alberta C1426ANZ
Argentina
Status: Recruiting Contact: N/A
Facility: Site AR54005
Cordoba, British Columbia X5004FHP
Argentina
Status: Recruiting Contact: N/A
Facility: Site AR54006
La Rioja, Ontario 5300
Argentina
Status: Recruiting Contact: N/A
Facility: Site AR54004
Mendoza, Ontario M5500AYB
Argentina
Status: Recruiting Contact: N/A
Facility: Site AR54001
Rosario, Ontario 2000
Argentina
Status: Recruiting Contact: N/A
Facility: Site AR54002
San Miguel, Ontario T400GTB
Argentina
Status: Recruiting Contact: N/A
Facility: Site AR54012
Tucuman, Ontario T4000IAK
Argentina
Status: Recruiting Contact: N/A
Facility: Site AR54003
Viedma, Quebec 8500
Argentina
Status: Recruiting Contact: N/A
Facility: Site AU61003
Box Hill, Quebec 3128
Australia
Status: Recruiting Contact: N/A
Facility: Site AUS61001
Douglas, 4814
Australia
Status: Recruiting Contact: N/A
Facility: Site AUS61004
Heidelberg, 3084
Australia
Status: Recruiting Contact: N/A
Facility: Site AUS61002
Macquarie Park, 2109
Australia
Status: Recruiting Contact: N/A
Facility: Site AUS61006
South Australia, 5112
Australia
Status: Recruiting Contact: N/A
Facility: Site AU61005
South Brisbane, 4101
Australia
Status: Recruiting Contact: N/A
Facility: Site BE32003
Brussels, 1200
Belgium
Status: Recruiting Contact: N/A
Facility: Site BE32002
Ghent, 9000
Belgium
Status: Recruiting Contact: N/A
Facility: Site BE32001
Liege, 4000
Belgium
Status: Recruiting Contact: N/A
Facility: Site BE32007
Lueven, 3000
Belgium
Status: Recruiting Contact: N/A
Facility: Site BE32006
Roeselare, 8800
Belgium
Status: Recruiting Contact: N/A
Facility: Site CA11004
Calgary, T2N 4N2
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11003
Edmonton, T6G 1Z2
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11006
Vancouver, V5Z 4E6
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11002
Hamilton, L8V 1C3
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11009
London, N6A 5A5
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11011
Oshawa, L1G 2B9
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11012
Toronto, M4N 3M5
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11005
Toronto, M5G 2M9
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11010
Montreal, H2X 0A9
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11001
Montreal, H3T 1E2
Canada
Status: Recruiting Contact: N/A
Facility: Site CA11008
Quebec, G1R 2J6
Canada
Status: Recruiting Contact: N/A
Facility: Site CN86001
Beijing, 100036
China
Status: Recruiting Contact: N/A
Facility: Site CN86004
Beijing, 100050
China
Status: Recruiting Contact: N/A
Facility: Site CN86005
Beijing, 100191
China
Status: Recruiting Contact: N/A
Facility: Site CN86017
Nanjing, 210008
China
Status: Recruiting Contact: N/A
Facility: Site CZ42006
Brno, 656 91
Czechia
Status: Recruiting Contact: N/A
Facility: Site CZ42001
Hradec Kralove, 500 05
Czechia
Status: Recruiting Contact: N/A
Facility: Site CZ42004
Olomouc, 779 00
Czechia
Status: Recruiting Contact: N/A
Facility: Site CZ42005
Praha 4-Krc, 140 59
Czechia
Status: Recruiting Contact: N/A
Facility: Site DK45001
Aalborg, 9100
Denmark
Status: Recruiting Contact: N/A
Facility: Site DK45003
Aarhus N, 8200
Denmark
Status: Recruiting Contact: N/A
Facility: Site FR33014
Bordeaux, 33000
France
Status: Recruiting Contact: N/A
Facility: Site FR33016
Lyon, 69373
France
Status: Recruiting Contact: N/A
Facility: Site FR33003
Nice Cedex 2, 06189
France
Status: Recruiting Contact: N/A
Facility: Site FR33020
Pierre-Bénite, 69495
France
Status: Recruiting Contact: N/A
Facility: Site FR33013
Strasbourg, 67200
France
Status: Recruiting Contact: N/A
Facility: Site FR33017
TOURS Cedex 09, 37044
France
Status: Recruiting Contact: N/A
Facility: Site FR33011
Villejuif-Cedex-France, 94805
France
Status: Recruiting Contact: N/A
Facility: Site DE49003
Berlin, 10117
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49013
Bielefeld, 33611
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49016
Düsseldorf, 40225
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49014
Erlangen, 91054
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49011
Essen, 45147
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49007
Frankfurt am Main, 60488
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49015
Gottingen, 37099
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49005
Heidelberg, 69120
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49009
Herne, 44649
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49006
Jena, 07747
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49001
Lubeck, 23538
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49008
Magdeburg, 39120
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49012
Mannheim, 68167
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49002
Munchen, 81675
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49004
Tübingen, 72076
Germany
Status: Recruiting Contact: N/A
Facility: Site DE49010
Ulm, 89081
Germany
Status: Recruiting Contact: N/A
Facility: Site HU36003
Budapest, 1083
Hungary
Status: Recruiting Contact: N/A
Facility: Site HU36002
Budapest, 1122
Hungary
Status: Recruiting Contact: N/A
Facility: Site HU36006
Debrecen, 4032
Hungary
Status: Recruiting Contact: N/A
Facility: Site HU36001
Nyiregyhaza, 4400
Hungary
Status: Recruiting Contact: N/A
Facility: Site HU36005
Szolnok, 5004
Hungary
Status: Recruiting Contact: N/A
Facility: Site IL97203
Beer Sheva, 84101
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97201
Haifa, 31096
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97209
Holon, 58100
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97206
Jerusalem, 91120
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97202
Kfar Saba, 44281
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97208
Petach Tikva, 49414
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97211
Rehovot, 76100
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97210
Tel Aviv, 64239
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97204
Tel Hashomer, 52621
Israel
Status: Recruiting Contact: N/A
Facility: Site IL97205
Zerifin, 70300
Israel
Status: Recruiting Contact: N/A
Facility: Site IT39005
Areezo, 52100
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39008
Candiolo, 10060
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39009
Cremona, 26100
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39006
Genova, 16132
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39003
Meldola, 47014
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39014
Milano, 20132
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39007
Milano, 20141
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39004
Pisa, 56126
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39002
Terni, 05100
Italy
Status: Recruiting Contact: N/A
Facility: Site IT39001
Verona, 37134
Italy
Status: Recruiting Contact: N/A
Facility: Site KR82001
Daejeon, 188663
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site KR82002
Goyang-si, 105077
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site KR82008
Hwasun, 123056
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site KR82004
Seongnam-si, 125284
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site KR82003
Seoul, 603074
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site KR82005
Seoul, 644013
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site KR82007
Seoul, 357502
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site KR82006
Seoul, 195271
Korea, Republic of
Status: Recruiting Contact: N/A
Facility: Site NL31005
Amsterdam, Noord-Holland, 197082
Netherlands
Status: Recruiting Contact: N/A
Facility: Site NL31002
Amsterdam, 197758
Netherlands
Status: Recruiting Contact: N/A
Facility: Site NL31001
Amsterdam, 430032
Netherlands
Status: Recruiting Contact: N/A
Facility: Site NL31007
Leeuwarden, 197758
Netherlands
Status: Recruiting Contact: N/A
Facility: Site NL31004
Nieuwegein, 625041
Netherlands
Status: Recruiting Contact: N/A
Facility: Site NL31003
Rotterdam, 450000
Netherlands
Status: Recruiting Contact: N/A
Facility: Site NL31006
Utrecht, 119074
Netherlands
Status: Recruiting Contact: N/A
Facility: Site PL48002
Warszawa, 169610
Poland
Status: Recruiting Contact: N/A
Facility: Site SG65001
Singapore, 46014
Singapore
Status: Recruiting Contact: N/A
Facility: Site SG65002
Singapore, 4031
Singapore
Status: Recruiting Contact: N/A
Facility: Site SG65003
Singapore, 3010
Singapore
Status: Recruiting Contact: N/A
Facility: Site ES34017
Barcelona, 7000
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34010
Barcelona, 8401
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34006
Barcelona, 83301
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34001
Barcelona, 333
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34008
Barcelona, 40447
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34013
Cordoba, 40705
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34021
Lugo, 70403
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34018
Madrid, 10002
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34002
Madrid, 11217
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34003
Madrid, 10330
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34015
Madrid, 10400
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34004
Manresa, 50200
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34020
Pamplona, 90110
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34016
Sabadell, 10700
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34012
Santander, 40002
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34007
Sevilla, 10400
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34019
Valencia, 6100
Spain
Status: Recruiting Contact: N/A
Facility: Site ES34009
Valencia, 6230
Spain
Status: Recruiting Contact: N/A
Facility: Site CH41004
Basel, 07059
Switzerland
Status: Recruiting Contact: N/A
Facility: Site CH41002
Bern, 22030
Switzerland
Status: Recruiting Contact: N/A
Facility: Site CH41001
Chur, 34093
Switzerland
Status: Recruiting Contact: N/A
Facility: Site CH41003
Winterthur, 34214
Switzerland
Status: Recruiting Contact: N/A
Facility: Site TW88603
Kaohsiung, 81450
Taiwan
Status: Recruiting Contact: N/A
Facility: Site TW88602
Kweishan, 42080
Taiwan
Status: Recruiting Contact: N/A
Facility: Site TW88607
Taichung, 44280
Taiwan
Status: Recruiting Contact: N/A
Facility: Site TW88606
Taichung, G12 0YN
Taiwan
Status: Recruiting Contact: N/A
Facility: Site TW88604
Tainan, EC1M 6BQ
Taiwan
Status: Recruiting Contact: N/A
Facility: Site TW88605
Taipei, W6 8RF
Taiwan
Status: Recruiting Contact: N/A
Facility: Site TW88601
Taipei, OX3 7LE
Taiwan
Status: Recruiting Contact: N/A
Facility: Site TH66004
Bangkok, PL6 8DH
Thailand
Status: Recruiting Contact: N/A
Facility: Site TH66003
Bangkok, PR2 9HT
Thailand
Status: Recruiting Contact: N/A
Facility: Site TH66005
Chiang Mai, S10 2RX
Thailand
Status: Recruiting Contact: N/A
Facility: Site TH66002
HatYai, SO16 6YD
Thailand
Status: Recruiting Contact: N/A
Facility: Site TH66006
Krung Thep Maha Nakhon,
Thailand
Status: Recruiting Contact: N/A
Facility: Site TH66007
Muang,
Thailand
Status: Recruiting Contact: N/A
Facility: Site TH66001
Ratchathewi,
Thailand
Status: Recruiting Contact: N/A
Facility: Site TR90007
Ankara,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90009
Ankara,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90005
Antalya,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90004
Edirne,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90008
Istanbul,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90003
Istanbul,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90002
Istanbul,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90001
Konya,
Turkey
Status: Recruiting Contact: N/A
Facility: Site TR90006
Malatya,
Turkey
Status: Recruiting Contact: N/A
Facility: Site UK44005
Glasgow,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Site UK44001
London,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Site UK44009
London,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Site UK44006
Oxford,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Site UK44010
Plymouth,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Site UK44002
Preston,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Site UK44003
Sheffield,
United Kingdom
Status: Recruiting Contact: N/A
Facility: Site UK44008
Southampton,
United Kingdom
Status: Recruiting Contact: N/A